{'output': [['Abbvie Inc.', 'COMP', 'Announce', 'Reduction In Tax Rate', 'ECON_INDICATOR'], ['Abbvie Inc.', 'COMP', 'Plan', 'Significant Investment', 'FIN_INSTRUMENT', 'US', 'GPE'], ['Abbvie Inc.', 'COMP', 'Plan', 'Advance Neuroscience Pipeline', 'CONCEPT'], ['Risankizumab', 'PRODUCT', 'Can Be', '$5 Billion Drug', 'FIN_INSTRUMENT', 'By 2025', 'TIME'], ['Upadacitinib', 'PRODUCT', 'Can Reach', '$6.5 Billion Sales', 'FIN_INSTRUMENT', 'By 2025', 'TIME', 'With Six Indications', 'PRODUCT'], ['Abbvie', 'COMP', 'Expects', 'Move At Least Ten Drugs', 'PRODUCT', 'To Clinical Trials', 'EVENT', 'In Next 12 Months', 'TIME'], ['Abbvie Inc.', 'COMP', 'Will Look', 'Ways To Return Additional Cash', 'FIN_INSTRUMENT', 'To Shareholders', 'PERSON']]}